NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 721
(Total Views: 314)
Posted On: 06/21/2019 5:34:06 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Continues to Demonstrate Effectiveness in Lab Testing
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) patented drug-delivery platform, DehydraTECH, has exhibited continued success in recent animal lab tests by delivering cannabinoids to the bloodstream faster than conventional cannabinoid formulations (http://nnw.fm/fsKW4). A recent article discussing the company reads, “Lab tests and actual licensed use in the cannabis industry have proved that DehydraTECH’s long-chain fatty acid (“LCFA”) formulation is able to deliver cannabinoids faster than formulations with medium-chain triglyceride (“MCT”) oils, such as coconut oil. DehydraTECH also offers the most advanced flavor and aroma-profile masking techniques in the industry. The groundbreaking technology could negate the need for artificial chemical masking agents or flavoring agents/sweeteners that mask the bitter flavors and aromas of cannabis. . . . Over the entire 60 minutes of the study, the DehydraTECH LCFA formulation delivered a CBD blood concentration level that was 334 percent higher than the level identified in animals that received the MCT oil formulation. The lab tests on animals compared how quickly a DehydraTECH formulation containing LCFA could deliver cannabinoids to the bloodstream, as compared to a concentration-matched conventional industry cannabinoid edible formulation with MCT oil. Coconut oil is commonly used due to its luxurious taste and mouth-feel, which can hide unpleasant cannabis flavors.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) patented drug-delivery platform, DehydraTECH, has exhibited continued success in recent animal lab tests by delivering cannabinoids to the bloodstream faster than conventional cannabinoid formulations (http://nnw.fm/fsKW4). A recent article discussing the company reads, “Lab tests and actual licensed use in the cannabis industry have proved that DehydraTECH’s long-chain fatty acid (“LCFA”) formulation is able to deliver cannabinoids faster than formulations with medium-chain triglyceride (“MCT”) oils, such as coconut oil. DehydraTECH also offers the most advanced flavor and aroma-profile masking techniques in the industry. The groundbreaking technology could negate the need for artificial chemical masking agents or flavoring agents/sweeteners that mask the bitter flavors and aromas of cannabis. . . . Over the entire 60 minutes of the study, the DehydraTECH LCFA formulation delivered a CBD blood concentration level that was 334 percent higher than the level identified in animals that received the MCT oil formulation. The lab tests on animals compared how quickly a DehydraTECH formulation containing LCFA could deliver cannabinoids to the bloodstream, as compared to a concentration-matched conventional industry cannabinoid edible formulation with MCT oil. Coconut oil is commonly used due to its luxurious taste and mouth-feel, which can hide unpleasant cannabis flavors.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼